Last updated: February 16, 2026
Product Overview
NDC 62011-0481 corresponds to Brentuximab Vedotin, marketed as Adcetris. It is an antibody-drug conjugate (ADC) approved for treating Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Approved by the FDA in 2011, it has expanded indications and maintains a significant market share in oncologic biologics.
Market Size and Demand Drivers
Current Market Size
- The global market for ADCs was valued at approximately $2.6 billion in 2022.
- Brentuximab Vedotin accounted for around 18% of ADC sales in 2022, with estimated revenues near $470 million.
- The mono-therapy segment dominates initial treatment lines; combination therapy segments are increasing due to ongoing clinical trials.
Key Demand Drivers
- Increased adoption in Hodgkin lymphoma treatment.
- Expansion into first-line therapy, pending regulatory approvals and clinical trial results.
- Growing use in pediatric populations and relapsed/refractory cases.
- Off-label usage in other CD30-expressing malignancies.
Market Competition
- Competes with other ADCs like polatuzumab vedotin and Inotuzumab ozogamicin.
- The emergence of biosimilars is limited due to patent protections and ADC complexity.
- Competitors primarily target similar indications with different mechanisms or drug delivery approaches.
Regulatory and Patent Landscape
Regulatory Status
- Approved for relapsed/refractory classical Hodgkin lymphoma (cHL) and sALCL.
- Ongoing trials for first-line cHL and other CD30-positive conditions.
- Fast-track designations or orphan drug status influence market exclusivity.
Patent Status
- Original patents expired legally in key markets in 2022.
- Extended patent protections through secondary patents and formulations until 2024-2026.
- Patent litigations and biosimilar development are ongoing, potentially affecting pricing and market entry.
Pricing Dynamics and Projections
Historical Pricing
- Current list prices range from $7,500 to $9,500 per vial, with a typical treatment course costing approximately $90,000 to $150,000.
- US wholesale acquisition cost (WAC): around $8,590 per 50 mg vial (as of 2023).
Pricing Trends
- Prices have increased annually at an average rate of 3–5% since launch.
- Discounts and rebates influence actual payer costs.
- The high cost reflects ADC manufacturing complexity and the targeted mechanism.
Price Projections
- In the next 2–3 years, list prices may stabilize or increase moderately (1–3% annually).
- Biosimilar competition, expected from 2024 onwards in certain markets, could reduce prices by 20–30% depending on regulatory approval and market uptake.
- US reimbursement policies, including the shift towards value-based agreements, could pressure prices downward.
Future Market and Price Outlook
| Time Frame |
Market Size Projection |
Price Outlook |
Key Factors |
| 2023–2025 |
$500M – $550M |
Stable to slightly decreasing (1–3%) |
Increased usage, expanded indications, biosimilar entry forecast |
| 2026–2030 |
$600M – $700M |
Potential decline (10–20%) |
Biosimilar competition intensifies, payer negotiations |
Market Expansion Opportunities
- New indications could boost sales.
- Combination regimens might expand prescribing.
- Pricing could soften with biosimilar integration.
Key Considerations for Stakeholders
- Manufacturers must balance R&D costs with price competitiveness amid biosimilar threats.
- Payers seek value-based models to mitigate high costs.
- Investors should monitor clinical trial outcomes, patent status, and biosimilar developments.
Key Takeaways
- NDC 62011-0481, Brentuximab Vedotin, holds a significant position within ADCs, with revenues around $470 million in 2022.
- The drug's high price reflects manufacturing complexity and exclusivity protections; prices have historically increased annually.
- Patent expirations and biosimilar entries forecast potential price reductions beginning in 2024-2026.
- Market growth depends on expanded indications and combination strategies, but pricing pressures are probable due to biosimilar competition and payer reforms.
- Long-term market stability hinges on regulatory approvals, patent protections, and healthcare policy adjustments.
FAQs
1. When is biosimilar competition expected for Brentuximab Vedotin?
Biosimilars are projected to enter the US and European markets around 2024–2026, contingent on regulatory approvals and patent litigation outcomes.
2. How does pricing for Brentuximab Vedotin compare internationally?
Prices vary widely. US prices are approximately $8,500–$9,500 per vial, whereas European prices tend to be 20–30% lower due to negotiated reimbursement and healthcare policy differences.
3. Are there ongoing clinical trials that could influence future market size?
Yes. Trials evaluating first-line therapy combinations and other CD30-positive malignancies could expand indications and product utilization.
4. What are the main factors affecting the drug’s pricing?
Manufacturing costs, patent protections, clinical efficacy, competition, and healthcare policy reforms influence pricing dynamics.
5. How might healthcare payers influence the drug's future pricing?
Payers are adopting value-based contracts and negotiating discounts, which could pressure list prices downward over time.
Sources:
- IQVIA. (2023). Global Oncology Market Reports.
- FDA. (2011). Approval of Brentuximab Vedotin.
- AnalyzePharma. (2023). ADC Market Trends.
- NICE. (2022). Price and Access Reports.
- PhRMA. (2022). Intellectual Property and Biosimilar Strategies.
